Sgt. Manry contracted West Nile virus encephalitis in July 2006, becoming paralyzed from the waist down. Three weeks after his first symptoms, Sgt. Manry and his physician began GenoMed's treatment protocol, which they credit with speeding his recovery. But despite heroic effort, Sgt. Manry still cannot walk without assistance nearly a year later.

Sgt. Manry, who is scheduled to lose his police job in two months because of his continued paralysis, said, "I don't want anybody to have to go through what I did. I just wish I'd known about GenoMed's protocol sooner."

Added Sgt. Manry, "In my case it took over a week before West Nile virus was even confirmed. GenoMed's treatment should be started as a precautionary measure even before confirmation by the CDC lab."

Said GenoMed's CEO and Chief Medical Officer, David Moskowitz MD, "Mr. Manry has put in a superhuman effort to recover from this devastating disease, which has been well documented (http://www.topix.net/search/article?q=%22Donnie+Manry%22, and http://www.donniemanry.info). Our experience with other patients suggests that he would have gotten a lot better a lot faster if he'd begun our treatment right away, within the first two days rather than three weeks later."

Added Dr. Moskowitz, "The sooner brain inflammation is turned off, the lower the risk of paralysis. Knowing about our treatment ahead of time could make the difference between a quick recovery instead of prolonged paralysis."

About GenoMed

Since 2003, GenoMed has been using safe, already existing, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 83% treatment success rate (20 of 24 patients). The first 8 patients were published three years ago in a peer-reviewed medical journal. GenoMed still has the only published treatment for West Nile virus encephalitis in the medical literature. Last summer GenoMed extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, www.genomed.com, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.